written on 21.04.2014

Report: Biopharma CEOs score 'supersalaries' even as sales decline


Eli Lilly&#39;s John Lechleiter was one of six pharma CEOs to make the <em>New York Times</em>&nbsp;2013 executive-pay ranking, but he wasn&#39;t at the top of the list of highly paid drug industry execs. That position went to Abbott&#39;s Miles White, who saw his pay rise 8% to $20.5 million, placing him in the 13th spot overall on the <em>NYT</em>&nbsp;list.